750 Corporate Drive
115 articles about Glenmark Pharmaceuticals
Glenmark and Cediprof Announce Exclusive Distribution Agreement in the United States for US FDA Approved Mixed Amphetamines Immediate-Release Tablets
Glenmark Pharmaceuticals Inc., USA and Cediprof, Inc. have entered into an exclusive supply and distribution agreement for Cediprof's FDA-approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg, the generic version of Adderall®1 Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Teva Women's Health, Inc.
Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials
Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex® 1 Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.
Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched their Fingolimod Capsules, 0.5 mg, the generic version of Gilenya ®1 Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.
SARS-CoV-2 typically enters the body via the nose or mouth. Because of this, many think a nasal spray vaccine would do a better job of preventing COVID-19 infection and cutting transmission than an injection.
2/14/2022Clinical Catch-Up for February 14
The COVID-19 pandemic has seen a full-blown effort from biopharma and researchers to develop new drugs and test old ones against the disease, with highly mixed results.
Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray
Ryaltris™ is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray approved by the FDA for the treatment of symptoms of Seasonal Allergic Rhinitis in adults and pediatric patients 12 years of age and older.
SaNOtize inks agreement with Indian biotech Glenmark to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets
SaNOtize Research and Development Corp. and Glenmark Pharmaceuticalsannounced an exclusive long-term strategic partnership to manufacture, market and distribute SaNOtize’s breakthrough Nitric Oxide Nasal Spray for COVID-19 treatment, in India and other Asian markets including Singapore, Malaysia Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.
7/29/2021Kaiser Permanente has reportedly filed a lawsuit against drug maker Merck for allegedly allowing a "pay-for-delay" scheme that cost the former millions of dollars.
7/27/2020It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
Glenmark Pharmaceutical’s Antiviral Drug Favipiravir Hits the Mark in Small, Phase III COVID-19 S...
7/23/2020An antiviral drug, favipiravir, developed by Glenmark Pharmaceuticals, boosted the time it takes COVID-19 patients with mild to moderate symptoms to improve their health in a Phase III study.
7/2/2020Biopharma and life sciences companies provide updates on their pipelines and business plans.
The U.S. Justice Department charged Glenmark Pharmaceuticals, headquartered in India, with conspiring with other generic drug companies to increase and hold prices for the cholesterol drug pravastatin between May 2013 and December 2015.
Glenmark Becomes the First Pharmaceutical Company in India to Receive Regulatory Approval for Oral Antiviral Favipiravir, for the Treatment of Mild to Moderate COVID-19
Manufacturing and marketing approval granted as part of accelerated approval process, considering the emergency situation of the COVID-19 outbreak in India
Glenmark to Commence New Phase 3 Clinical Trial on Combination of Two Anti-viral Drugs Favipiravir and Umifenovir in Hospitalized Patients of Moderate COVID-19 in India
Glenmark Pharmaceuticals, a global pharmaceutical company, announced a new randomized, open-label study to test the combined efficacy of two antiviral drugs Favipiravir and Umifenovir as a potential COVID-19 treatment strategy.
COVID-19 patients from over 10 leading government and private hospitals in India are being enrolled for the study
Following months of concerns regarding the potential contamination of ranitidine-based products with known carcinogens, the U.S. Food and Drug Administration is asking manufacturers to immediately withdraw all prescription and over-the-counter drugs from the market.
Another recall has been issued for ranitidine tablets due to the presence of a carcinogen contaminant.
Horizon Discovery Signs License Agreement With Glenmark Pharmaceuticals for GS Knockout CHO Cell Line for Manufacture of Biotherapeutics
Glenmark signs full commercial-use license for Horizon’s gene-edited CHO cells